ES2528665T3 - Fabricación de vacunas amplificadoras que tienen dosis de antígeno reducidas - Google Patents
Fabricación de vacunas amplificadoras que tienen dosis de antígeno reducidas Download PDFInfo
- Publication number
- ES2528665T3 ES2528665T3 ES07825522.1T ES07825522T ES2528665T3 ES 2528665 T3 ES2528665 T3 ES 2528665T3 ES 07825522 T ES07825522 T ES 07825522T ES 2528665 T3 ES2528665 T3 ES 2528665T3
- Authority
- ES
- Spain
- Prior art keywords
- vaccines
- amplifying
- manufacture
- reduced antigen
- antigen doses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 229960003983 diphtheria toxoid Drugs 0.000 abstract 3
- 229960000814 tetanus toxoid Drugs 0.000 abstract 3
- 206010043376 Tetanus Diseases 0.000 abstract 1
- 206010013023 diphtheria Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Un procedimiento de fabricación de una vacuna, en el que la vacuna comprende toxoide diftérico y toxoide tetánico, y en el que el procedimiento comprende las etapas de combinar (i) un primer volumen que comprende toxoide diftérico y toxoide tetánico a una relación de difteria: tétanos entre 2 : 1 y 3 : 1 (medida en unidades Lf) con (ii) un segundo volumen que comprende toxoide tetánico pero no toxoide diftérico.
Description
Claims (1)
-
imagen1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0616306.7A GB0616306D0 (en) | 2006-08-16 | 2006-08-16 | Vaccines |
GB0616306 | 2006-08-16 | ||
PCT/IB2007/003255 WO2008020328A2 (en) | 2006-08-16 | 2007-08-15 | Manufacture of booster vaccines having reduced antigen doses |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2528665T3 true ES2528665T3 (es) | 2015-02-11 |
Family
ID=37081096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES07825522.1T Active ES2528665T3 (es) | 2006-08-16 | 2007-08-15 | Fabricación de vacunas amplificadoras que tienen dosis de antígeno reducidas |
Country Status (7)
Country | Link |
---|---|
US (1) | US20100158940A1 (es) |
EP (1) | EP2073841B1 (es) |
JP (2) | JP5090452B2 (es) |
CN (1) | CN101522217B (es) |
ES (1) | ES2528665T3 (es) |
GB (1) | GB0616306D0 (es) |
WO (1) | WO2008020328A2 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0822633D0 (en) * | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
US9950062B2 (en) | 2009-09-02 | 2018-04-24 | Glaxosmithkline Biologicals Sa | Compounds and compositions as TLR activity modulators |
BR112013005134A2 (pt) | 2010-09-01 | 2018-04-24 | Novartis Ag | adsorção de imunopotenciadores em sais metálicos insolúveis |
US20140112950A1 (en) | 2011-03-02 | 2014-04-24 | Manmohan Singh | Combination vaccines with lower doses of antigen and/or adjuvant |
CN102526717A (zh) * | 2011-11-25 | 2012-07-04 | 成都康华生物制品有限公司 | 一种吸附无细胞百白破联合疫苗的制备方法 |
US20150125486A1 (en) * | 2012-03-08 | 2015-05-07 | Novartis Ag | Adjuvanted formulations of pediatric antigens |
CN104159602B (zh) * | 2012-03-08 | 2017-10-24 | 葛兰素史密丝克莱恩生物有限公司 | 加强疫苗的含佐剂制剂 |
CN103908667A (zh) * | 2014-04-18 | 2014-07-09 | 中国医学科学院医学生物学研究所 | 吸附无细胞百白破-Sabin株脊髓灰质炎联合疫苗及制备方法 |
CN104707134A (zh) * | 2015-03-27 | 2015-06-17 | 成都欧林生物科技股份有限公司 | 一种无细胞百日破联合疫苗及其制备方法 |
EP3530285B1 (en) * | 2016-10-20 | 2023-08-09 | KM Biologics Co., Ltd. | METHOD FOR PRODUCING HIB CONJUGATE VACCINE USING PRP WITH
LOWERED MOLECULAR WEIGHT |
KR102426041B1 (ko) * | 2017-08-01 | 2022-07-29 | 주식회사 녹십자 | 냉동 및 해동 과정을 포함하는 백일해균 유래 단백질 수득 방법 |
WO2020165920A1 (en) * | 2019-02-12 | 2020-08-20 | Biological E Limited | Multivalent vaccine composition |
CN111053898B (zh) * | 2019-12-26 | 2023-05-16 | 北京科兴中维生物技术有限公司 | 一种疫苗组合物及其应用 |
CN114748616A (zh) * | 2022-05-23 | 2022-07-15 | 中国医学科学院医学生物学研究所 | 一种成人青少年用无细胞百白破联合疫苗及其制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5554125A (en) * | 1987-07-08 | 1996-09-10 | Reynolds; David L. | Prefilled vial syringe |
HU220236B (hu) * | 1992-05-23 | 2001-11-28 | Smithkline Beecham Biologicals S.A. | Hepatitis B felszíni antigént és egyéb antigéneket tartalmazó, kombinált oltóanyagok |
US6696065B1 (en) * | 1995-05-04 | 2004-02-24 | Aventis Pastuer Limited | Acellular pertussis vaccines and methods of preparation thereof |
JP3280675B2 (ja) * | 1996-07-02 | 2002-05-13 | コノート ラボラトリーズ リミテッド | 多価dtpポリオワクチン |
GB9623233D0 (en) * | 1996-11-07 | 1997-01-08 | Smithkline Beecham Biolog | Vaccine composition |
US20010014331A1 (en) * | 1996-11-07 | 2001-08-16 | Smithkline Beecham Biologicals S.A. | Acellular pertussis vaccine with diphthriae-and tetanus-toxoids |
ATE316797T1 (de) * | 1997-09-15 | 2006-02-15 | Sanofi Pasteur Msd | Verfahren zur herstellung multivalenter impfstoffe |
EP1004314A1 (fr) * | 1998-11-26 | 2000-05-31 | Pasteur Merieux MSD | Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée |
KR100401423B1 (ko) * | 2001-01-10 | 2003-10-17 | 주식회사 엘지생명과학 | 혼합 백신의 제조 방법 |
-
2006
- 2006-08-16 GB GBGB0616306.7A patent/GB0616306D0/en not_active Ceased
-
2007
- 2007-08-15 US US12/310,188 patent/US20100158940A1/en not_active Abandoned
- 2007-08-15 EP EP07825522.1A patent/EP2073841B1/en active Active
- 2007-08-15 JP JP2009524255A patent/JP5090452B2/ja not_active Expired - Fee Related
- 2007-08-15 CN CN200780037461.4A patent/CN101522217B/zh not_active Expired - Fee Related
- 2007-08-15 ES ES07825522.1T patent/ES2528665T3/es active Active
- 2007-08-15 WO PCT/IB2007/003255 patent/WO2008020328A2/en active Application Filing
-
2012
- 2012-09-12 JP JP2012200460A patent/JP2012236864A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN101522217B (zh) | 2014-07-16 |
EP2073841B1 (en) | 2014-11-26 |
US20100158940A1 (en) | 2010-06-24 |
JP2010500398A (ja) | 2010-01-07 |
WO2008020328A2 (en) | 2008-02-21 |
WO2008020328A3 (en) | 2008-06-19 |
GB0616306D0 (en) | 2006-09-27 |
EP2073841A2 (en) | 2009-07-01 |
JP2012236864A (ja) | 2012-12-06 |
CN101522217A (zh) | 2009-09-02 |
JP5090452B2 (ja) | 2012-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2528665T3 (es) | Fabricación de vacunas amplificadoras que tienen dosis de antígeno reducidas | |
CY1121211T1 (el) | Εμβολιο ιου ερπητα ζωστηρα | |
ES2640012T3 (es) | Nanoparticulas de dioxido de silicio y el uso de las mismas para la vacunacion | |
AR058543A1 (es) | Nueva composicion de vacuna potenciada con un adyuvante liposomal | |
ES2529577T3 (es) | Vacunas contra la malaria | |
ES2691965T3 (es) | Vigas con sección transversal en forma de U | |
ES2613400T3 (es) | Método para mejorar la fagocitosis de células que exponen fosfatidilserina | |
CY1118492T1 (el) | Φαρμακοτεχνικες μορφες εμβολιου norovirus | |
ES2544974T3 (es) | Base, productos que contienen la misma, métodos de preparación y usos de los mismos | |
CL2007001185A1 (es) | Formulaciones que estabilizan o inhiben la agregacion inducida por silicona de un conjugado de polisacarido-proteina;formulaciones que estabilizan o inhiben la agregacion inducida por silicona de un conjugado de polisacarido-proteina;formulaciones que estabilizan o inhiben la agregacion inducida por silicona de una composicion de proteina de n meningitidis | |
CO6160335A2 (es) | Vacuna | |
CR11122A (es) | Vacuna de influenza de emulsion de aceite en agua | |
CL2011000914A1 (es) | Vacuna combinada estable completamente liquida que comprende antigenos difterico, tetanico, pertusico acelular, de haemophilus influenzae, y de virus de poliomielitis en donde el antigeno se haemophilus influenzae no esta sustancialmente absorbido sobre ningun adyuvante; y proceso de fabricacion. | |
ES2552651T3 (es) | Composición inyectable de polidesoxirribonucleótido para el tratamiento de enfermedades osteoarticulares | |
IL299897B1 (en) | Devices and methods for administering multiple units of drug | |
CR11812A (es) | Vacuna de vesicula, de membrana externa nativa multivalente del meningococo, metodo para su fabricacion y uso | |
ECSP088490A (es) | Forma farmacéutica oral que contiene como principios activos un inhibidor de la bomba de protones junto con ácido acetilsalicílico | |
ES2513691T3 (es) | Preparación transdérmica | |
AR108718A2 (es) | Composición | |
WO2007052057A3 (en) | Adminstration routes for priming/boosting with influenza vaccines | |
AR071828A1 (es) | Producto de tabaco para uso oral | |
CL2015001111A1 (es) | Composición coadyuvante que comprende un hidrato de carbono unido al quitosano formando una base de schiff; formulación de vacuna que la comprende; método de elaboración; y uso de la vacuna. | |
CY1114190T1 (el) | Νεα μορφη χορηγησης της ρασεκαδοτριλης | |
CO6321162A2 (es) | Una vacuna que comprende una cantidad inmunogenica de un antigeno en somastatina y un adyuvante | |
CU23819A3 (es) | Sustancias inmunogénicas mucosales que comprenden un adyuvante a base de ácido poliinosínico-ácido policitidílico |